Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1995 1
1999 2
2001 1
2002 2
2003 4
2005 1
2006 6
2007 3
2008 1
2009 3
2010 6
2011 4
2012 9
2013 8
2014 3
2015 12
2016 11
2017 14
2018 9
2019 10
2020 16
2021 19
2022 28
2023 18
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Classic Hodgkin Lymphoma"
Page 1
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Connors JM, et al. Nat Rev Dis Primers. 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. Nat Rev Dis Primers. 2020. PMID: 32703953 Review.
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in the tumour microenvironment. ...The goal of multimodality therapy is to minimize lifelong residual treatment-associated toxicity while mainta …
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in t …
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano J, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S. Harker-Murray P, et al. Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118. Blood. 2023. PMID: 36564047 Free PMC article. Clinical Trial.
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. ...Patients rec …
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) without co …
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Mei MG, et al. Blood. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. Blood. 2022. PMID: 35316328 Free PMC article. Clinical Trial.
This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic cell transplantation (AHCT) in relapsed/refractory (RR) classical Hodgkin …
This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salva …
Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Fan Z, et al. Am J Surg Pathol. 2003 Oct;27(10):1346-56. doi: 10.1097/00000478-200310000-00007. Am J Surg Pathol. 2003. PMID: 14508396
Prominent sclerosis was identified in approximately 20% of cases and was frequently seen in recurrent disease. Clinical follow-up was obtained on 56 patients, including 26 patients who had not had recurrence of disease and 30 patients who had recurr …
Prominent sclerosis was identified in approximately 20% of cases and was frequently seen in recurrent disease. Clinical follow …
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH. Herrera AF, et al. Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 2017 Dec 11. Blood. 2018. PMID: 29229594 Free PMC article. Clinical Trial.
In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL). Patients received up to 4 cycles of com …
In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy …
Biomarkers of response to PD-1/PD-L1 inhibition.
Maleki Vareki S, Garrigós C, Duran I. Maleki Vareki S, et al. Crit Rev Oncol Hematol. 2017 Aug;116:116-124. doi: 10.1016/j.critrevonc.2017.06.001. Epub 2017 Jun 9. Crit Rev Oncol Hematol. 2017. PMID: 28693793 Free article. Review.
A number of immunomodulatory agents that target immune system checkpoints such as the cytotoxic T-lymphocyte antigen 4 (CTLA-4), the programmed death-1 (PD-1) or its ligand (PD-L1), have received regulatory approval for the treatment of multiple cancers including malignant melano …
A number of immunomodulatory agents that target immune system checkpoints such as the cytotoxic T-lymphocyte antigen 4 (CTLA-4), the program …
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Geoerger B, et al. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812554 Clinical Trial.
Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc decision. The data cutoff for this interim analysis was Sept 3, 2018. ...Final results of KEYNOTE-051, expected by September, 2022, with the pos …
Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc deci …
Classic Hodgkin Lymphoma - Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers.
Perry AM, Smith LB, Bagg A. Perry AM, et al. Acta Med Acad. 2021 Apr;50(1):110-125. doi: 10.5644/ama2006-124.329. Acta Med Acad. 2021. PMID: 34075767 Free article. Review.
The aim of this paper is to review morphologic, immunophenotypic, and molecular features of classic Hodgkin lymphoma, as well as different prognostic markers in this neoplasm. Classic Hodgkin lymphoma (CHL) accounts for 15-25% of all lymp …
The aim of this paper is to review morphologic, immunophenotypic, and molecular features of classic Hodgkin lymphoma, a …
Follicular non-Hodgkin's lymphoma.
Hayashi D, Lee JC, Devenney-Cakir B, Zaim S, Ounadjela S, Solal-Céligny P, Juweid M, Guermazi A. Hayashi D, et al. Clin Radiol. 2010 May;65(5):408-20. doi: 10.1016/j.crad.2010.01.010. Epub 2010 Mar 15. Clin Radiol. 2010. PMID: 20380942 Review.
Follicular non-Hodgkin's lymphoma (NHL) is a unique subtype of NHL, which is indolent, incurable with a high prevalence of residual mass after treatment, and may transform to more aggressive NHL. ...Imaging is essential in every step of the management of patients wi …
Follicular non-Hodgkin's lymphoma (NHL) is a unique subtype of NHL, which is indolent, incurable with a high prevalence of res …
An evaluation of pembrolizumab for classical Hodgkin lymphoma.
Manji F, Laister RC, Kuruvilla J. Manji F, et al. Expert Rev Hematol. 2022 Apr;15(4):285-293. doi: 10.1080/17474086.2022.2061947. Epub 2022 Apr 11. Expert Rev Hematol. 2022. PMID: 35389317 Review.
INTRODUCTION: Pembrolizumab is an immune checkpoint inhibitor (ICI) targeted against the programmed death 1 (PD-1) pathway, a key pathway in the biology of Classical Hodgkin lymphoma (cHL). Anti-PD-1 antibodies are approved for use in relapsed/refractory cHL …
INTRODUCTION: Pembrolizumab is an immune checkpoint inhibitor (ICI) targeted against the programmed death 1 (PD-1) pathway, a key pathway in …
166 results